Find clinical trials for Triple Negative Breast Cancer in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Triple Negative Breast Cancer trials near Hanyang, Seoul, KOR:
of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...
Phase 1, Phase 2
Seoul, South Korea and 31 other locations
(SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC).The pri...
Phase 1, Phase 2
Seoul, South Korea and 14 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Seoul, South Korea and 283 other locations
and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...
Phase 2, Phase 3
Seoul, Seoul-teukbyeolsi [Seoul], South Korea and 290 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Seoul, South Korea and 374 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Seoul, South Korea and 39 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Seoul, South Korea and 506 other locations
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...
Phase 3
Seoul, Korea, Republic of and 128 other locations
with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...
Phase 3
Seoul, South Korea and 77 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Seoul, South Korea and 227 other locations
Clinical trials
Research sites
Resources
Legal